Background: Significance of pancreatic autoantibodies determined by using exocrine pancreas (PAB) and recombinant pancreas antigens (rPAB), as well as importance of autoantibodies against goblet cells (GAB) are not known in pediatric patients with inflammatory bowel disease (IBD). Our aim was to determine the complex analysis of PAB, rPAB, GAB, antibodies against Saccharomyces cerevisiae (ASCA), and perinuclear components of neutrophils (pANCA) in pediatric IBD patients. Moreover, association with NOD2/CARD15 and disease phenotype was determined.
Introduction
Inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC) are chronic relapsing and remitting disorders of the gastrointestinal tract. The pathogenesis of IBD is complex and multifactorial. Current evidence suggests that IBD results from an aberrant immune response and loss of tolerance to the normal intestinal flora, leading to Copyright © ESPGHAN and NASPGHAN. All rights reserved. 4 chronic inflammation of the gut in a genetically susceptible host (1) . This hypothesis is supported by the occurrence of antibodies directed to microbial antigens and by the identification of NOD2/CARD15, as susceptibility genes to CD (2) . Besides genetic predisposition and environmental factors, autoimmune mechanisms are suggested to play a vital part in the pathogenesis of IBD. The search for the underlying trigger of the abnormal intestinal inflammation characteristics of IBD has led to the discovery of antibodies present specifically in the blood of patients with CD and/or UC. Several autoantibodies have been described in IBD.
Relatively low prevalence of exocrine pancreas antibodies (PAB) was detected in adult patients with CD (27-39%) using indirect immunofluorescence (IIF) (3,4). However, increased prevalence of PAB has been found in un-affected first-degree relatives of IBD patients, suggesting a genetic origin of these antibodies (5) . The determination of autoantibodies against exocrine pancreas by IIF using human cells transfected with the recently identified proteoglycans CUZD1 and GP2 as recombinant target antigens (recombinant pancreas antigen 1 and 2: rPAg1 and rPAg2) represents a new dimension in the serological diagnosis of IBD (6, 7) . The studies conducted in adult patients provided conflicting data regarding association between PAB and CD phenotype (4, 8, 9) .
Autoantibodies against intestinal goblet cells (GAB) have previously been described in UC with a prevalence of 28-30% and in 20% of first-degree relatives to IBD patients (3,10). Recent studies, however, suggested a much lower prevalence in both diseases (4, 11) .
Moreover, PAB, rPAB and GAB have not been examined in a large cohort of pediatric IBD, and data on the specificity and sensitivity are contradictory in adult IBD.
The two most intensively studied conservative antibodies are autoantibodies to neutrophils [perinuclear anti-neutrophil cytoplasmic antibodies (pANCA)], primarily associated with UC and anti-Saccharomyces cerevisiae antibodies (ASCA), primarily
Copyright © ESPGHAN and NASPGHAN. All rights reserved. 5 associated with CD (2, 12) . In pediatric IBD the sensitivity/specificity of pANCA in UC ranged between 57-83%, and 65% to 97% respectively, whereas in CD, ASCA showed a sensitivity/specificity in the range of 44% to 76%, and 88% to 95%, respectively (13, 14) .
ASCA positivity or high titers are associated with a complicated disease behavior (penetrating or stenosing disease) and could be useful markers for predicting need for surgery also in pediatric patients (15) (16) (17) . PANCA is noted for its association with "UC-like" CD phenotype (18, 19) .
The clinical importance of PAB and GAB is understudied in pediatric IBD patients.
The aim of our study was to determine the prevalence of PAB, rPAB, GAB, ASCA, and pANCA in patients with pediatric-onset IBD. In addition, we assessed the association between antibody profile and NOD2/CARD15 status, clinical presentation, response to treatment and extraintestinal manifestations. Ulcerative Colitis Index (PUCAI) for the UC group (21, 22) . Activity index >30 is defined as a moderate-severe disease, the index between 11-30 indicates a mild disease, and the index ≤10 refers to an inactive disease.
Patients and methods

Patients
Copyright © ESPGHAN and NASPGHAN. All rights reserved. 
Detection of NOD2/CARD15 mutations
Genomic DNA was isolated from whole blood using the QIAamp DNA Blood Mini Kit (QIAGEN, Germany). The three NOD2/CARD15 variants, Arg702Trp, Gly908Arg, Copyright © ESPGHAN and NASPGHAN. All rights reserved. 8 Leu1007fs, were typed using polymerase chain reaction/restriction fragment length polymorphism as previously described (22) . NOD2/CARD15 variants were detected by denaturing high-performance liquid chromatography (dHPLC, Wave DNA Fragment Analysis System, Transgenomic, UK). Sequence variation, observed in the dHPLC profile, was sequenced on both strands to confirm the alteration. Sequencing reactions were performed with the ABI BigDye Terminator Cycle Sequencing Kit v1.1 (Applied Biosystems, Foster City, CA) and samples were sequenced on an ABI Prism 310 Genetic Analyzer (Applied Biosystems). Genotyping was carried out at the National Haematology and Immunology Institute, Budapest, Hungary.
Statistical Analysis
Statistical analysis was carried out using Graph Pad Prism 5 (GraphPad, San Diego CA, USA). The presence of ASCA, pANCA, PAB, rPAB, and GAB were compared between the
IBD and control cohorts, as well as within subgroups of IBD patients using χ 2 -test and
Fisher's exact test. The differences of age between in subgroups of patients were assessed by Mann-Whitney-test. Logistic regression analysis was also performed to assess the complex associations between clinical phenotype and the serology profile. A p value of <0.05 was considered as significant.
Results
Characteristics of patients with IBD
The clinical phenotype of CD and UC patients is shown in Table 1 . Median age at diagnosis was 13.9 years. Fifty-one percent of CD patients and 50% of UC patients had active disease, whereas 49% of CD patients and 50% of UC patients were in remission at the time of taking blood samples. Forty pediatric CD patients (38.8%) developed penetrating and /or stricturing 
